ACADIA Pharmaceuticals (ACAD) News Today

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher today following a series of bullish analyst actions and solid second-quarter results.

• Positive Sentiment: Royal Bank of Canada lifted its price target on ACAD from $39.00 to $40.00 and maintained an “outperform” rating, highlighting confidence in the company’s growth prospects. ACADIA Pharmaceuticals Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: JMP Securities raised its price objective on ACAD from $37.00 to $38.00 and reiterated a “market outperform” rating, suggesting further upside potential. JMP Securities Issues Positive Forecast for ACADIA Pharmaceuticals
• Positive Sentiment: HC Wainwright boosted its FY2027 EPS estimate for ACAD to $2.49 (from $2.43), kept a “Buy” rating, and set a $32.00 target, outpacing consensus expectations.
• Positive Sentiment: Second-quarter results topped estimates as strong Nuplazid and Daybue sales drove revenue growth, underscoring operational momentum. Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
• Positive Sentiment: Acadia raised 2025 Nuplazid guidance to $665 million–$690 million as Daybue accelerates community uptake, signaling upward revisions in core-product forecasts. Acadia Raises 2025 Nuplazid Guidance to $665M–$690M
• Neutral Sentiment: Mizuho nudged its target up from $23.00 to $24.00 but kept a “neutral” rating, reflecting balanced views on valuation. Mizuho Issues Positive Forecast for ACADIA Pharmaceuticals
• Neutral Sentiment: ACADIA reaffirmed FY2025 revenue guidance of $1.0 billion–$1.1 billion versus a consensus of $1.1 billion, indicating stable top-line expectations.
• Negative Sentiment: The Goldman Sachs Group increased its price target from $15.00 to $17.00 but maintained a “sell” rating, implying limited near-term upside. ACADIA Pharmaceuticals Price Target Raised to $17.00 at The Goldman Sachs Group
• Negative Sentiment: Leerink Partners cut its FY2025 EPS forecast for ACAD from $0.55 to $0.50, reflecting more conservative near-term profitability views.